- Report
- June 2026
- 200 Pages
Global
From €2675EUR$2,990USD£2,288GBP
- Report
- August 2026
- 282 Pages
Global
From €5234EUR$5,850USD£4,476GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 200 Pages
Global
From €7149EUR$7,990USD£6,114GBP
- Report
- September 2025
- 150 Pages
Global
From €3982EUR$4,450USD£3,405GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,190USD£3,098GBP
- Report
- November 2023
- 135 Pages
Global
From €3579EUR$4,000USD£3,061GBP
- Report
- June 2025
- 150 Pages
Global
From €3355EUR$3,750USD£2,869GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1342EUR$1,500USD£1,148GBP
- Report
- December 2024
- 30 Pages
Global
From €2461EUR$2,750USD£2,104GBP
- Report
- September 2024
- 343 Pages
Global
From €7113EUR$7,950USD£6,083GBP
- Report
- July 2024
- 150 Pages
Global
From €3355EUR$3,750USD£2,869GBP
- Report
- April 2023
- 117 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- June 2025
- 400 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- March 2023
- 147 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- May 2024
- 137 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 135 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- January 2023
- 85 Pages
Europe
From €1342EUR$1,500USD£1,148GBP
- Report
- January 2024
- 156 Pages
United States
€3400EUR$3,800USD£2,908GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more